Compare WLY & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WLY | ANIP |
|---|---|---|
| Founded | 1807 | 2001 |
| Country | United States | United States |
| Employees | 5200 | N/A |
| Industry | Books | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.9B |
| IPO Year | N/A | 1999 |
| Metric | WLY | ANIP |
|---|---|---|
| Price | $50.32 | $78.53 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $110.00 |
| AVG Volume (30 Days) | ★ 690.4K | 297.5K |
| Earning Date | 06-16-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.50% | N/A |
| EPS Growth | N/A | ★ 419.23 |
| EPS | N/A | ★ 1.28 |
| Revenue | N/A | ★ $206,547,000.00 |
| Revenue This Year | $1.04 | $21.01 |
| Revenue Next Year | $2.36 | $17.59 |
| P/E Ratio | ★ $15.84 | $60.72 |
| Revenue Growth | N/A | ★ 2.47 |
| 52 Week Low | $28.38 | $62.61 |
| 52 Week High | $53.24 | $99.50 |
| Indicator | WLY | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 59.24 | 40.84 |
| Support Level | $48.45 | $77.16 |
| Resistance Level | $53.24 | $83.66 |
| Average True Range (ATR) | 1.98 | 2.58 |
| MACD | -0.25 | -0.72 |
| Stochastic Oscillator | 48.33 | 16.01 |
John Wiley & Sons Inc is a publisher and a trusted leader in research and learning. The company segment includes: Research, which includes the reporting lines of Research Publishing and Research Solutions, and Learning includes the Academic and Professional reporting lines and consists of publishing, courseware, and assessments. Its industry-principal content, services, platforms, and knowledge networks are tailored to meet the evolving needs of its customers and partners, including researchers, students, instructors, professionals, institutions, and corporations. The company empowers knowledge-seekers to transform today's obstacles into tomorrow's brightest opportunities. For more than two centuries, the company has been delivering on its timeless mission to unlock human potential.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.